0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global G-CSF Biosimilars Market Research Report 2023
Published Date: February 2023
|
Report Code: QYRE-Auto-7F9012
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global G CSF Biosimilars Market Insights Forecast to 2028
BUY CHAPTERS

Global G-CSF Biosimilars Market Research Report 2023

Code: QYRE-Auto-7F9012
Report
February 2023
Pages:93
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Global G-CSF Biosimilars Market

Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein containing 174 amino acids with a molecular weight of about 20000.
The global G-CSF Biosimilars market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.
This report analyzes the worldwide markets for G-CSF Biosimilars in US$ by the following Product Segments: Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor
Company profiles are primarily based on public domain information including company
Merck & Co.
Sanofi
Johnson & Johnson
Gilead Science
GlaxoSmithKline
AbbVie
Amgen
AstraZeneca
Bayer
Pfizer
Novartis
Roche

Report Scope

This report aims to provide a comprehensive presentation of the global market for G-CSF Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding G-CSF Biosimilars.
The G-CSF Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global G-CSF Biosimilars market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the G-CSF Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.

Key Segmentations

By Company

  • Pfizer
  • Novartis
  • Roche
  • Merck & Co.
  • Sanofi
  • Johnson & Johnson
  • Gilead Science
  • GlaxoSmithKline
  • AbbVie
  • Amgen
  • AstraZeneca
  • Bayer

Segment by Type

  • Human Growth Hormone
  • Erythropoietin
  • Monoclonal Antibodies
  • Insulin
  • Interferon
  • Granulocyte-Colony Stimulating Factor

Segment by Application

  • Blood Disorders
  • Oncology Diseases
  • Chronic And Autoimmune Diseases
  • Growth Hormone Deficiencies

Consumption by Region

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • Taiwan
  • Indonesia
  • Thailand
  • Malaysia
  • Philippines
  • Vietnam
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • U.A.E

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of G-CSF Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of G-CSF Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

Scope of Global G-CSF Biosimilars Market Report

Report MetricDetails
Report NameGlobal G-CSF Biosimilars Market
Base Year2022
Forecasted years2023-2029
Forecast unitsUSD
Report coverageRevenue and volume forecast, company share, competitive landscape, growth factors and trends
Geographic regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa
1 G-CSF Biosimilars Market Overview
1.1 Product Overview and Scope of G-CSF Biosimilars
1.2 G-CSF Biosimilars Segment by Type
1.2.1 Global G-CSF Biosimilars Market Value Comparison by Type (2023-2029)
1.2.2 Human Growth Hormone
1.2.3 Erythropoietin
1.2.4 Monoclonal Antibodies
1.2.5 Insulin
1.2.6 Interferon
1.2.7 Granulocyte-Colony Stimulating Factor
1.3 G-CSF Biosimilars Segment by Application
1.3.1 Global G-CSF Biosimilars Market Value by Application: (2023-2029)
1.3.2 Blood Disorders
1.3.3 Oncology Diseases
1.3.4 Chronic And Autoimmune Diseases
1.3.5 Growth Hormone Deficiencies
1.4 Global G-CSF Biosimilars Market Size Estimates and Forecasts
1.4.1 Global G-CSF Biosimilars Revenue 2018-2029
1.4.2 Global G-CSF Biosimilars Sales 2018-2029
1.4.3 Global G-CSF Biosimilars Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 G-CSF Biosimilars Market Competition by Manufacturers
2.1 Global G-CSF Biosimilars Sales Market Share by Manufacturers (2018-2023)
2.2 Global G-CSF Biosimilars Revenue Market Share by Manufacturers (2018-2023)
2.3 Global G-CSF Biosimilars Average Price by Manufacturers (2018-2023)
2.4 Global G-CSF Biosimilars Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of G-CSF Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of G-CSF Biosimilars, Product Type & Application
2.7 G-CSF Biosimilars Market Competitive Situation and Trends
2.7.1 G-CSF Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest G-CSF Biosimilars Players Market Share by Revenue
2.7.3 Global G-CSF Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 G-CSF Biosimilars Retrospective Market Scenario by Region
3.1 Global G-CSF Biosimilars Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global G-CSF Biosimilars Global G-CSF Biosimilars Sales by Region: 2018-2029
3.2.1 Global G-CSF Biosimilars Sales by Region: 2018-2023
3.2.2 Global G-CSF Biosimilars Sales by Region: 2024-2029
3.3 Global G-CSF Biosimilars Global G-CSF Biosimilars Revenue by Region: 2018-2029
3.3.1 Global G-CSF Biosimilars Revenue by Region: 2018-2023
3.3.2 Global G-CSF Biosimilars Revenue by Region: 2024-2029
3.4 North America G-CSF Biosimilars Market Facts & Figures by Country
3.4.1 North America G-CSF Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America G-CSF Biosimilars Sales by Country (2018-2029)
3.4.3 North America G-CSF Biosimilars Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe G-CSF Biosimilars Market Facts & Figures by Country
3.5.1 Europe G-CSF Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe G-CSF Biosimilars Sales by Country (2018-2029)
3.5.3 Europe G-CSF Biosimilars Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific G-CSF Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific G-CSF Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific G-CSF Biosimilars Sales by Country (2018-2029)
3.6.3 Asia Pacific G-CSF Biosimilars Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America G-CSF Biosimilars Market Facts & Figures by Country
3.7.1 Latin America G-CSF Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America G-CSF Biosimilars Sales by Country (2018-2029)
3.7.3 Latin America G-CSF Biosimilars Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa G-CSF Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa G-CSF Biosimilars Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa G-CSF Biosimilars Sales by Country (2018-2029)
3.8.3 Middle East and Africa G-CSF Biosimilars Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global G-CSF Biosimilars Sales by Type (2018-2029)
4.1.1 Global G-CSF Biosimilars Sales by Type (2018-2023)
4.1.2 Global G-CSF Biosimilars Sales by Type (2024-2029)
4.1.3 Global G-CSF Biosimilars Sales Market Share by Type (2018-2029)
4.2 Global G-CSF Biosimilars Revenue by Type (2018-2029)
4.2.1 Global G-CSF Biosimilars Revenue by Type (2018-2023)
4.2.2 Global G-CSF Biosimilars Revenue by Type (2024-2029)
4.2.3 Global G-CSF Biosimilars Revenue Market Share by Type (2018-2029)
4.3 Global G-CSF Biosimilars Price by Type (2018-2029)
5 Segment by Application
5.1 Global G-CSF Biosimilars Sales by Application (2018-2029)
5.1.1 Global G-CSF Biosimilars Sales by Application (2018-2023)
5.1.2 Global G-CSF Biosimilars Sales by Application (2024-2029)
5.1.3 Global G-CSF Biosimilars Sales Market Share by Application (2018-2029)
5.2 Global G-CSF Biosimilars Revenue by Application (2018-2029)
5.2.1 Global G-CSF Biosimilars Revenue by Application (2018-2023)
5.2.2 Global G-CSF Biosimilars Revenue by Application (2024-2029)
5.2.3 Global G-CSF Biosimilars Revenue Market Share by Application (2018-2029)
5.3 Global G-CSF Biosimilars Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer G-CSF Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer G-CSF Biosimilars Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis G-CSF Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Novartis G-CSF Biosimilars Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche G-CSF Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Roche G-CSF Biosimilars Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Merck & Co.
6.4.1 Merck & Co. Corporation Information
6.4.2 Merck & Co. Description and Business Overview
6.4.3 Merck & Co. G-CSF Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck & Co. G-CSF Biosimilars Product Portfolio
6.4.5 Merck & Co. Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi G-CSF Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Sanofi G-CSF Biosimilars Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson G-CSF Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Johnson & Johnson G-CSF Biosimilars Product Portfolio
6.6.5 Johnson & Johnson Recent Developments/Updates
6.7 Gilead Science
6.6.1 Gilead Science Corporation Information
6.6.2 Gilead Science Description and Business Overview
6.6.3 Gilead Science G-CSF Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Gilead Science G-CSF Biosimilars Product Portfolio
6.7.5 Gilead Science Recent Developments/Updates
6.8 GlaxoSmithKline
6.8.1 GlaxoSmithKline Corporation Information
6.8.2 GlaxoSmithKline Description and Business Overview
6.8.3 GlaxoSmithKline G-CSF Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.8.4 GlaxoSmithKline G-CSF Biosimilars Product Portfolio
6.8.5 GlaxoSmithKline Recent Developments/Updates
6.9 AbbVie
6.9.1 AbbVie Corporation Information
6.9.2 AbbVie Description and Business Overview
6.9.3 AbbVie G-CSF Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.9.4 AbbVie G-CSF Biosimilars Product Portfolio
6.9.5 AbbVie Recent Developments/Updates
6.10 Amgen
6.10.1 Amgen Corporation Information
6.10.2 Amgen Description and Business Overview
6.10.3 Amgen G-CSF Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Amgen G-CSF Biosimilars Product Portfolio
6.10.5 Amgen Recent Developments/Updates
6.11 AstraZeneca
6.11.1 AstraZeneca Corporation Information
6.11.2 AstraZeneca G-CSF Biosimilars Description and Business Overview
6.11.3 AstraZeneca G-CSF Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.11.4 AstraZeneca G-CSF Biosimilars Product Portfolio
6.11.5 AstraZeneca Recent Developments/Updates
6.12 Bayer
6.12.1 Bayer Corporation Information
6.12.2 Bayer G-CSF Biosimilars Description and Business Overview
6.12.3 Bayer G-CSF Biosimilars Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Bayer G-CSF Biosimilars Product Portfolio
6.12.5 Bayer Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 G-CSF Biosimilars Industry Chain Analysis
7.2 G-CSF Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 G-CSF Biosimilars Production Mode & Process
7.4 G-CSF Biosimilars Sales and Marketing
7.4.1 G-CSF Biosimilars Sales Channels
7.4.2 G-CSF Biosimilars Distributors
7.5 G-CSF Biosimilars Customers
8 G-CSF Biosimilars Market Dynamics
8.1 G-CSF Biosimilars Industry Trends
8.2 G-CSF Biosimilars Market Drivers
8.3 G-CSF Biosimilars Market Challenges
8.4 G-CSF Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global G-CSF Biosimilars Market Value Comparison by Type (2023-2029) & (US$ Million)
    Table 2. Global G-CSF Biosimilars Market Value Comparison by Application (2023-2029) & (US$ Million)
    Table 3. Global G-CSF Biosimilars Market Competitive Situation by Manufacturers in 2022
    Table 4. Global G-CSF Biosimilars Sales (K Units) of Key Manufacturers (2018-2023)
    Table 5. Global G-CSF Biosimilars Sales Market Share by Manufacturers (2018-2023)
    Table 6. Global G-CSF Biosimilars Revenue (US$ Million) by Manufacturers (2018-2023)
    Table 7. Global G-CSF Biosimilars Revenue Share by Manufacturers (2018-2023)
    Table 8. Global Market G-CSF Biosimilars Average Price (USD/Unit) of Key Manufacturers (2018-2023)
    Table 9. Global Key Players of G-CSF Biosimilars, Industry Ranking, 2021 VS 2022 VS 2023
    Table 10. Global Key Manufacturers of G-CSF Biosimilars, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of G-CSF Biosimilars, Product Type & Application
    Table 12. Global Key Manufacturers of G-CSF Biosimilars, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global G-CSF Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in G-CSF Biosimilars as of 2022)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global G-CSF Biosimilars Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 17. Global G-CSF Biosimilars Sales by Region (2018-2023) & (K Units)
    Table 18. Global G-CSF Biosimilars Sales Market Share by Region (2018-2023)
    Table 19. Global G-CSF Biosimilars Sales by Region (2024-2029) & (K Units)
    Table 20. Global G-CSF Biosimilars Sales Market Share by Region (2024-2029)
    Table 21. Global G-CSF Biosimilars Revenue by Region (2018-2023) & (US$ Million)
    Table 22. Global G-CSF Biosimilars Revenue Market Share by Region (2018-2023)
    Table 23. Global G-CSF Biosimilars Revenue by Region (2024-2029) & (US$ Million)
    Table 24. Global G-CSF Biosimilars Revenue Market Share by Region (2024-2029)
    Table 25. North America G-CSF Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 26. North America G-CSF Biosimilars Sales by Country (2018-2023) & (K Units)
    Table 27. North America G-CSF Biosimilars Sales by Country (2024-2029) & (K Units)
    Table 28. North America G-CSF Biosimilars Revenue by Country (2018-2023) & (US$ Million)
    Table 29. North America G-CSF Biosimilars Revenue by Country (2024-2029) & (US$ Million)
    Table 30. Europe G-CSF Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 31. Europe G-CSF Biosimilars Sales by Country (2018-2023) & (K Units)
    Table 32. Europe G-CSF Biosimilars Sales by Country (2024-2029) & (K Units)
    Table 33. Europe G-CSF Biosimilars Revenue by Country (2018-2023) & (US$ Million)
    Table 34. Europe G-CSF Biosimilars Revenue by Country (2024-2029) & (US$ Million)
    Table 35. Asia Pacific G-CSF Biosimilars Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
    Table 36. Asia Pacific G-CSF Biosimilars Sales by Region (2018-2023) & (K Units)
    Table 37. Asia Pacific G-CSF Biosimilars Sales by Region (2024-2029) & (K Units)
    Table 38. Asia Pacific G-CSF Biosimilars Revenue by Region (2018-2023) & (US$ Million)
    Table 39. Asia Pacific G-CSF Biosimilars Revenue by Region (2024-2029) & (US$ Million)
    Table 40. Latin America G-CSF Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 41. Latin America G-CSF Biosimilars Sales by Country (2018-2023) & (K Units)
    Table 42. Latin America G-CSF Biosimilars Sales by Country (2024-2029) & (K Units)
    Table 43. Latin America G-CSF Biosimilars Revenue by Country (2018-2023) & (US$ Million)
    Table 44. Latin America G-CSF Biosimilars Revenue by Country (2024-2029) & (US$ Million)
    Table 45. Middle East & Africa G-CSF Biosimilars Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
    Table 46. Middle East & Africa G-CSF Biosimilars Sales by Country (2018-2023) & (K Units)
    Table 47. Middle East & Africa G-CSF Biosimilars Sales by Country (2024-2029) & (K Units)
    Table 48. Middle East & Africa G-CSF Biosimilars Revenue by Country (2018-2023) & (US$ Million)
    Table 49. Middle East & Africa G-CSF Biosimilars Revenue by Country (2024-2029) & (US$ Million)
    Table 50. Global G-CSF Biosimilars Sales (K Units) by Type (2018-2023)
    Table 51. Global G-CSF Biosimilars Sales (K Units) by Type (2024-2029)
    Table 52. Global G-CSF Biosimilars Sales Market Share by Type (2018-2023)
    Table 53. Global G-CSF Biosimilars Sales Market Share by Type (2024-2029)
    Table 54. Global G-CSF Biosimilars Revenue (US$ Million) by Type (2018-2023)
    Table 55. Global G-CSF Biosimilars Revenue (US$ Million) by Type (2024-2029)
    Table 56. Global G-CSF Biosimilars Revenue Market Share by Type (2018-2023)
    Table 57. Global G-CSF Biosimilars Revenue Market Share by Type (2024-2029)
    Table 58. Global G-CSF Biosimilars Price (USD/Unit) by Type (2018-2023)
    Table 59. Global G-CSF Biosimilars Price (USD/Unit) by Type (2024-2029)
    Table 60. Global G-CSF Biosimilars Sales (K Units) by Application (2018-2023)
    Table 61. Global G-CSF Biosimilars Sales (K Units) by Application (2024-2029)
    Table 62. Global G-CSF Biosimilars Sales Market Share by Application (2018-2023)
    Table 63. Global G-CSF Biosimilars Sales Market Share by Application (2024-2029)
    Table 64. Global G-CSF Biosimilars Revenue (US$ Million) by Application (2018-2023)
    Table 65. Global G-CSF Biosimilars Revenue (US$ Million) by Application (2024-2029)
    Table 66. Global G-CSF Biosimilars Revenue Market Share by Application (2018-2023)
    Table 67. Global G-CSF Biosimilars Revenue Market Share by Application (2024-2029)
    Table 68. Global G-CSF Biosimilars Price (USD/Unit) by Application (2018-2023)
    Table 69. Global G-CSF Biosimilars Price (USD/Unit) by Application (2024-2029)
    Table 70. Pfizer Corporation Information
    Table 71. Pfizer Description and Business Overview
    Table 72. Pfizer G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 73. Pfizer G-CSF Biosimilars Product
    Table 74. Pfizer Recent Developments/Updates
    Table 75. Novartis Corporation Information
    Table 76. Novartis Description and Business Overview
    Table 77. Novartis G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 78. Novartis G-CSF Biosimilars Product
    Table 79. Novartis Recent Developments/Updates
    Table 80. Roche Corporation Information
    Table 81. Roche Description and Business Overview
    Table 82. Roche G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 83. Roche G-CSF Biosimilars Product
    Table 84. Roche Recent Developments/Updates
    Table 85. Merck & Co. Corporation Information
    Table 86. Merck & Co. Description and Business Overview
    Table 87. Merck & Co. G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 88. Merck & Co. G-CSF Biosimilars Product
    Table 89. Merck & Co. Recent Developments/Updates
    Table 90. Sanofi Corporation Information
    Table 91. Sanofi Description and Business Overview
    Table 92. Sanofi G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 93. Sanofi G-CSF Biosimilars Product
    Table 94. Sanofi Recent Developments/Updates
    Table 95. Johnson & Johnson Corporation Information
    Table 96. Johnson & Johnson Description and Business Overview
    Table 97. Johnson & Johnson G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 98. Johnson & Johnson G-CSF Biosimilars Product
    Table 99. Johnson & Johnson Recent Developments/Updates
    Table 100. Gilead Science Corporation Information
    Table 101. Gilead Science Description and Business Overview
    Table 102. Gilead Science G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 103. Gilead Science G-CSF Biosimilars Product
    Table 104. Gilead Science Recent Developments/Updates
    Table 105. GlaxoSmithKline Corporation Information
    Table 106. GlaxoSmithKline Description and Business Overview
    Table 107. GlaxoSmithKline G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 108. GlaxoSmithKline G-CSF Biosimilars Product
    Table 109. GlaxoSmithKline Recent Developments/Updates
    Table 110. AbbVie Corporation Information
    Table 111. AbbVie Description and Business Overview
    Table 112. AbbVie G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 113. AbbVie G-CSF Biosimilars Product
    Table 114. AbbVie Recent Developments/Updates
    Table 115. Amgen Corporation Information
    Table 116. Amgen Description and Business Overview
    Table 117. Amgen G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 118. Amgen G-CSF Biosimilars Product
    Table 119. Amgen Recent Developments/Updates
    Table 120. AstraZeneca Corporation Information
    Table 121. AstraZeneca Description and Business Overview
    Table 122. AstraZeneca G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 123. AstraZeneca G-CSF Biosimilars Product
    Table 124. AstraZeneca Recent Developments/Updates
    Table 125. Bayer Corporation Information
    Table 126. Bayer Description and Business Overview
    Table 127. Bayer G-CSF Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
    Table 128. Bayer G-CSF Biosimilars Product
    Table 129. Bayer Recent Developments/Updates
    Table 130. Key Raw Materials Lists
    Table 131. Raw Materials Key Suppliers Lists
    Table 132. G-CSF Biosimilars Distributors List
    Table 133. G-CSF Biosimilars Customers List
    Table 134. G-CSF Biosimilars Market Trends
    Table 135. G-CSF Biosimilars Market Drivers
    Table 136. G-CSF Biosimilars Market Challenges
    Table 137. G-CSF Biosimilars Market Restraints
    Table 138. Research Programs/Design for This Report
    Table 139. Key Data Information from Secondary Sources
    Table 140. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of G-CSF Biosimilars
    Figure 2. Global G-CSF Biosimilars Market Value Comparison by Type (2023-2029) & (US$ Million)
    Figure 3. Global G-CSF Biosimilars Market Share by Type in 2022 & 2029
    Figure 4. Human Growth Hormone Product Picture
    Figure 5. Erythropoietin Product Picture
    Figure 6. Monoclonal Antibodies Product Picture
    Figure 7. Insulin Product Picture
    Figure 8. Interferon Product Picture
    Figure 9. Granulocyte-Colony Stimulating Factor Product Picture
    Figure 10. Global G-CSF Biosimilars Market Value Comparison by Application (2023-2029) & (US$ Million)
    Figure 11. Global G-CSF Biosimilars Market Share by Application in 2022 & 2029
    Figure 12. Blood Disorders
    Figure 13. Oncology Diseases
    Figure 14. Chronic And Autoimmune Diseases
    Figure 15. Growth Hormone Deficiencies
    Figure 16. Global G-CSF Biosimilars Revenue, (US$ Million), 2018 VS 2022 VS 2029
    Figure 17. Global G-CSF Biosimilars Market Size (2018-2029) & (US$ Million)
    Figure 18. Global G-CSF Biosimilars Sales (2018-2029) & (K Units)
    Figure 19. Global G-CSF Biosimilars Average Price (USD/Unit) & (2018-2029)
    Figure 20. G-CSF Biosimilars Report Years Considered
    Figure 21. G-CSF Biosimilars Sales Share by Manufacturers in 2022
    Figure 22. Global G-CSF Biosimilars Revenue Share by Manufacturers in 2022
    Figure 23. The Global 5 and 10 Largest G-CSF Biosimilars Players: Market Share by Revenue in 2022
    Figure 24. G-CSF Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
    Figure 25. Global G-CSF Biosimilars Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Figure 26. North America G-CSF Biosimilars Sales Market Share by Country (2018-2029)
    Figure 27. North America G-CSF Biosimilars Revenue Market Share by Country (2018-2029)
    Figure 28. U.S. G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 29. Canada G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 30. Europe G-CSF Biosimilars Sales Market Share by Country (2018-2029)
    Figure 31. Europe G-CSF Biosimilars Revenue Market Share by Country (2018-2029)
    Figure 32. Germany G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 33. France G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 34. U.K. G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 35. Italy G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 36. Russia G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 37. Asia Pacific G-CSF Biosimilars Sales Market Share by Region (2018-2029)
    Figure 38. Asia Pacific G-CSF Biosimilars Revenue Market Share by Region (2018-2029)
    Figure 39. China G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 40. Japan G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 41. South Korea G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 42. India G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 43. Australia G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 44. Taiwan G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 45. Indonesia G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 46. Thailand G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 47. Malaysia G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 48. Philippines G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 49. Latin America G-CSF Biosimilars Sales Market Share by Country (2018-2029)
    Figure 50. Latin America G-CSF Biosimilars Revenue Market Share by Country (2018-2029)
    Figure 51. Mexico G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 52. Brazil G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 53. Argentina G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 54. Middle East & Africa G-CSF Biosimilars Sales Market Share by Country (2018-2029)
    Figure 55. Middle East & Africa G-CSF Biosimilars Revenue Market Share by Country (2018-2029)
    Figure 56. Turkey G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 57. Saudi Arabia G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 58. U.A.E G-CSF Biosimilars Revenue Growth Rate (2018-2029) & (US$ Million)
    Figure 59. Global Sales Market Share of G-CSF Biosimilars by Type (2018-2029)
    Figure 60. Global Revenue Market Share of G-CSF Biosimilars by Type (2018-2029)
    Figure 61. Global G-CSF Biosimilars Price (USD/Unit) by Type (2018-2029)
    Figure 62. Global Sales Market Share of G-CSF Biosimilars by Application (2018-2029)
    Figure 63. Global Revenue Market Share of G-CSF Biosimilars by Application (2018-2029)
    Figure 64. Global G-CSF Biosimilars Price (USD/Unit) by Application (2018-2029)
    Figure 65. G-CSF Biosimilars Value Chain
    Figure 66. G-CSF Biosimilars Production Process
    Figure 67. Channels of Distribution (Direct Vs Distribution)
    Figure 68. Distributors Profiles
    Figure 69. Bottom-up and Top-down Approaches for This Report
    Figure 70. Data Triangulation
    Figure 71. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Pharmaceutical Aseptic Fill and Finish CMO Service Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-1R8980
Tue Feb 20 00:00:00 UTC 2024

Add to Cart

Global Quizartinib Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-3Q8625
Tue Feb 20 00:00:00 UTC 2024

Add to Cart

Global Octreotide Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-3X12361
Tue Feb 20 00:00:00 UTC 2024

Add to Cart

Global Veterinary Anesthesia Vaporizers Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-35M13226
Tue Feb 20 00:00:00 UTC 2024

Add to Cart